美罗华联合化疗对B细胞非霍奇金淋巴瘤患者临床病理的影响分析  

Analysis of influence of Mab Thera combined with chemotherapy on clinical pathology of B-cell nonHodgkin's lymphoma patients

作　　者：刘明阁[1,2] 宋魏[1,2] 张建波[1,2] 孙淼淼[1,2] 于庆凯[1,2] 

机构地区：[1]河南省肿瘤医院 [2]郑州大学附属肿瘤医院病理科,450003

出　　处：《中国实用医药》2015年第10期1-3,共3页China Practical Medicine

基　　金：河南省科技厅社会公益预研项目(项目编号:082103810505)

摘　　要：目的观察利妥昔单抗注射液(美罗华)联合化疗治疗B细胞非霍奇金淋巴瘤患者的临床效果。方法 62例B细胞非霍奇金淋巴瘤患者,随机分为观察组和对照组,每组31例,两组患者入院后均给予化疗,观察组患者另外给予美罗华治疗,连续治疗3个周期后观察两组患者的治疗效果和不良反应发生率。结果观察组患者治疗总有效率为90.32%,对照组治疗总有效率为67.74%,组间差异有统计学意义(P<0.05);观察组出现不良反应8例,对照组出现不良反应6例,组间差异无统计学意义(P>0.05)。结论临床上对B细胞非霍奇金淋巴瘤患者采用美罗华和化疗联合治疗,治疗效果理想,且无严重不良反应发生,具有较大的实用价值。Objective To observe the clinical effect of rituximab injection （MabThera） combined with chemotherapy in the treatment of B-cell non-Hodgkin＇ s lymphoma patients. Methods A total of 62 patients with B-cell non-Hodgkin＇ s lymphoma were randomly divided into observation group and control group, with 31 cases in each group. Both groups were given chemotherapy, and the observation group received additional MabThera for treatment. After 3 courses of treatment, observations were made on the curative effects and incidences of adverse reactions of the two groups. Results The total effective rate of the observation group was 90.32%, and that of the control group was 67.74%. The difference between the two groups had statistical significance （P〈0.05）. There were 8 cases with adverse reactions in the observation group, and 6 cases in the control pup. The difference was not statistically significant between the two groups （P〉0.05）. Conclusion Combination of MabThera and chemotherapy provides ideal effects in treating B-cell non-Hodgkin＇ s lymphoma patients without severe adverse reactions. It possesses great practical value.

关 键 词：利妥昔单抗注射液 化疗 B细胞非霍奇金淋巴瘤 临床疗效 

分 类 号：R733.1[医药卫生—肿瘤]